The global Portal Hypertension Management Market is predicted to be valued at US$ 3.05 billion in 2023, with a CAGR of 5% from 2023 to 2033. The market for portal hypertension management is expected to reach $4.97 billion by the end of the forecast period.
One of the most common causes of portal hypertension is cirrhosis. Cirrhosis is a type of liver disease that is characterised by scar tissue that replaces healthy liver cells. As a result, the increase in the number of persons affected by this ailment is expected to fuel market expansion. Males are more likely than females to get cirrhosis, according to the National Institute of Diabetes and Digestive and Kidney Diseases Trusted Source. As a result, it is projected that the elderly would contribute to market growth.
Because of high-cost technological advances in the health-care system and a rise in the prevalence and frequency of beta-blocker ingestion, North America has the biggest market share. Because of its expanding older population and higher diagnosis rate, Asia-Pacific has the second-largest market revenue. As the prevalence and occurrence of rare diseases, as well as the inpatient population, continue to expand, North America is predicted to account for the majority of the market in the future decade.
The expansion of the Liver Transplantation segment can be linked to the global increase in demand for transplantable organs. According to the US Department of Health and Human Services, around 122,913 diagnoses were ready for organ transplants in the United States in 2019. As a result, transplantation items produced for organ damage intervention are in high demand. As a result, the Liver Transplantation market is rising.
Competitive Landscape
Key players in the Portal Hypertension Management market are Ono Pharmaceutical Co., Ltd., Chiasma, Inc., Genextra S.p.a., Gilead Sciences, Inc., Debiovision, Inc., Govind Ballabh Pant Hospital, Dr. Falk Pharma GmbH, Novartis AG, Sun Pharmaceuticals Industries Ltd.
Get More Details@ https://www.futuremarketinsights.com/reports/portal-hypertension-management-market
Key Segments Profiled in the Portal Hypertension Management Industry Survey
By Treatment:
- Liver Transplantation
- Endoscopic Therapy
- Banding
- Balloon Tamponade
- Shunting Procedures
- Nonsurgical Transjugular Intrahepatic Portal Systemic Shunt
- Surgical Shun
- Drug Class
- Octapeptides
- Cofactors
- PDE5 Inhibitor
- Beta Blockers
By End Users:
- Hospitals
- Specialty Clinic
- Others
Global Hypertension Management Devices Market: OverviewHypertension is a key risk factor for cardiovascular diseases and continues to be a major cause of global morbidity and mortality.
Grab an Exclusive PDF Brochure of Hypertension Management Devices Market ReportKey Drivers of Global Hypertension Management Devices MarketResistant hypertension (RHTN) continues to contribute to the overall population’s cardiovascular morbidity and mortality.
This factor is anticipated to boost the growth of the global hypertension management devices market.Request COVID Analysis on Hypertension Management Devices Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=76551 Restraints of Global Hypertension Management Devices MarketNot all types of hypertension management devices are reimbursed.
A majority of health insurance plans in the U.S. do not cover hypertension management devices.Insurance benefits for hypertension management devices vary from payer to payer.
Some payers could cover monitors, but not additional support services provided by non-physicians.Some private insurance plans in the U.S. provide benefits only to beneficiaries who are enrolled in the disease management programs for HTN or other medical conditions that have increased risk of developing heart diseases and causing strokePre Book Hypertension Management Devices Market Report –https://www.transparencymarketresearch.com/checkout.php?rep_id=76551=SNorth America to Account for Major Share of Global Hypertension Management Devices MarketNorth America is likely to dominate the global hypertension management devices market during the forecast period due to rise in prevalence of hypertension as well as resistant hypertension, presence of major players, and increase in adoption of advanced devices to monitor hypertension.
According to the CDC, in 2017, nearly half a million deaths in the U.S. included hypertension as a primary or contributing cause.The hypertension management devices market in Asia Pacific is expected to expand at a high CAGR during the forecast period, owing to increase in the geriatric population with hypertension, rise in adoption of new treatment procedure to manage hypertension, surge in health care expenditure, and increase in awareness among people about preventive health care.Expanding Operations in Future?
